These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37143322)

  • 1. TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A.
    Jeon H; Jang SY; Kwak G; Yi YW; You MH; Park NY; Jo JH; Yang JW; Jang HJ; Jeong SY; Moon SK; Doo HM; Nahm M; Kim D; Chang JW; Choi BO; Hong YB
    Brain; 2023 Sep; 146(9):3608-3615. PubMed ID: 37143322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
    Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
    Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.
    Hanemann CO; Müller HW
    Trends Neurosci; 1998 Jul; 21(7):282-6. PubMed ID: 9683317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.
    Park NY; Kwak G; Doo HM; Kim HJ; Jang SY; Lee YI; Choi BO; Hong YB
    Curr Issues Mol Biol; 2021 Nov; 43(3):2011-2021. PubMed ID: 34889893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs.
    Shi L; Huang L; He R; Huang W; Wang H; Lai X; Zou Z; Sun J; Ke Q; Zheng M; Lu X; Pei Z; Su H; Xiang AP; Li W; Yao X
    Stem Cell Reports; 2018 Jan; 10(1):120-133. PubMed ID: 29276154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
    Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
    J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Charcot-Marie-Tooth disease and related inherited neuropathies.
    Murakami T; Garcia CA; Reiter LT; Lupski JR
    Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of peripheral myelin protein 22 in onion bulbs and Schwann cells of biopsied nerves from patients with Charcot-Marie-Tooth disease type 1A.
    Nishimura T; Yoshikawa H; Fujimura H; Sakoda S; Yanagihara T
    Acta Neuropathol; 1996 Nov; 92(5):454-60. PubMed ID: 8922056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
    Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
    Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PMP22 duplication dysregulates lipid homeostasis and plasma membrane organization in developing human Schwann cells.
    Prior R; Silva A; Vangansewinkel T; Idkowiak J; Tharkeshwar AK; Hellings TP; Michailidou I; Vreijling J; Loos M; Koopmans B; Vlek N; Agaser C; Kuipers TB; Michiels C; Rossaert E; Verschoren S; Vermeire W; de Laat V; Dehairs J; Eggermont K; van den Biggelaar D; Bademosi AT; Meunier FA; vandeVen M; Van Damme P; Mei H; Swinnen JV; Lambrichts I; Baas F; Fluiter K; Wolfs E; Van Den Bosch L
    Brain; 2024 Sep; 147(9):3113-3130. PubMed ID: 38743588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PMP22 expression in dermal nerve myelin from patients with CMT1A.
    Katona I; Wu X; Feely SM; Sottile S; Siskind CE; Miller LJ; Shy ME; Li J
    Brain; 2009 Jul; 132(Pt 7):1734-40. PubMed ID: 19447823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
    Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
    Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease.
    Fornasari BE; Ronchi G; Pascal D; Visigalli D; Capodivento G; Nobbio L; Perroteau I; Schenone A; Geuna S; Gambarotta G
    Exp Biol Med (Maywood); 2018 Feb; 243(4):370-374. PubMed ID: 29350067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
    Ha N; Choi YI; Jung N; Song JY; Bae DK; Kim MC; Lee YJ; Song H; Kwak G; Jeong S; Park S; Nam SH; Jung SC; Choi BO
    Br J Pharmacol; 2020 Nov; 177(22):5096-5113. PubMed ID: 33460073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages.
    Hanemann CO; Gabreëls-Fasten AA; Müller HW; Stoll G
    Brain; 1996 Oct; 119 ( Pt 5)():1461-9. PubMed ID: 8931571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
    Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
    Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited demyelinating neuropathies with micromutations of peripheral myelin protein 22 gene.
    Taioli F; Cabrini I; Cavallaro T; Acler M; Fabrizi GM
    Brain; 2011 Feb; 134(Pt 2):608-17. PubMed ID: 21252112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients.
    Lee S; Bazick H; Chittoor-Vinod V; Al Salihi MO; Xia G; Notterpek L
    Am J Pathol; 2018 Mar; 188(3):728-738. PubMed ID: 29246495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.
    Stavrou M; Kagiava A; Choudury SG; Jennings MJ; Wallace LM; Fowler AM; Heslegrave A; Richter J; Tryfonos C; Christodoulou C; Zetterberg H; Horvath R; Harper SQ; Kleopa KA
    J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35579942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A.
    Sancho S; Young P; Suter U
    Brain; 2001 Nov; 124(Pt 11):2177-87. PubMed ID: 11673320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.